CN103626993B - Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof - Google Patents
Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof Download PDFInfo
- Publication number
- CN103626993B CN103626993B CN201310541744.XA CN201310541744A CN103626993B CN 103626993 B CN103626993 B CN 103626993B CN 201310541744 A CN201310541744 A CN 201310541744A CN 103626993 B CN103626993 B CN 103626993B
- Authority
- CN
- China
- Prior art keywords
- glycol monomethyl
- monomethyl ether
- poly glycol
- soybean
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 52
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 52
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 37
- 244000068988 Glycine max Species 0.000 title claims abstract description 37
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 150000008104 phosphatidylethanolamines Chemical class 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 13
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 229920000151 polyglycol Polymers 0.000 claims abstract 29
- 239000010695 polyglycol Substances 0.000 claims abstract 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- -1 glycol monomethyl ether acyl chlorides Chemical class 0.000 claims description 17
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000003810 Jones reagent Substances 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims 4
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 229960004232 linoleic acid Drugs 0.000 claims 1
- 229960002969 oleic acid Drugs 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical class CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- YNQYZBDRJZVSJE-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl 2,3-di(octadecanoyloxy)propyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC YNQYZBDRJZVSJE-UHFFFAOYSA-M 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物药物辅料及其制备方法,属于医药化学领域。The invention relates to a polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative drug excipient and a preparation method thereof, belonging to the field of medicinal chemistry.
背景技术Background technique
聚乙二醇单甲醚(二硬脂酰基磷脂酰乙醇胺(脑磷脂)衍生物(MPEG-DSPE)是两亲性聚合物,他在水中可形成聚合物胶束,这种胶束是一种核-壳结构,尺寸在100-200nm。其通常是用于包覆疏水性药物,以增加疏水性药物在人体血液中的溶解度从而发挥药效。由于形成的这种小尺寸聚合物胶束外部是聚乙二醇分子链段,其可以在胶束外表面形成交错覆盖的致密构象云,形成较厚的立体位阻层,阻碍了人体血液内高密度脂蛋白的攻击和细胞的吞噬从而延长了药物在体内的存留时间,使其不至于在达到病变部位之前被消耗。同时这种纳米胶束利用肿瘤、炎症或高血压血管等损伤部位的毛细血管的通透性高于正常血管,同时淋巴排泄能力减弱,具有生物兼容的大分子、药物载体和分子聚集体在体内循环过程中更容易通过病理部位的血管进入组织内并聚集的效应(EPR效应)而具有被动靶向作用,从而使其在抗癌靶向药物中得到广泛的应用。Polyethylene glycol monomethyl ether (distearyl phosphatidylethanolamine (cephalin) derivative (MPEG-DSPE) is an amphiphilic polymer, which can form polymer micelles in water, which is a kind of Core-shell structure with a size of 100-200nm. It is usually used to coat hydrophobic drugs to increase the solubility of hydrophobic drugs in human blood to exert drug effects. Due to the formation of this small-sized polymer micelle It is a molecular chain segment of polyethylene glycol, which can form a dense conformational cloud covered by staggered on the outer surface of the micelles, forming a thicker steric hindrance layer, which hinders the attack of high-density lipoproteins in human blood and the phagocytosis of cells, thereby extending Increase the retention time of the drug in the body, so that it will not be consumed before reaching the lesion. At the same time, this kind of nano-micelle utilizes the permeability of the capillary in the damaged part of the tumor, inflammation or hypertensive blood vessel to be higher than that of the normal blood vessel, and at the same time The ability of lymphatic excretion is weakened, and biocompatible macromolecules, drug carriers and molecular aggregates are more likely to enter the tissue through the blood vessels of the pathological site and accumulate during the circulation in the body (EPR effect), so that they have a passive targeting effect. It has been widely used in anticancer targeted drugs.
目前抗癌靶向药物价格普遍较高,这与药物本身的原料来源和制备方法有重要关系,因此选择低成本的原料和简便的制备方法较为重要。目前报道的制备MPEG-DSPE的方法大致分为两大类,一类是直接使用聚乙二醇或聚乙二醇单甲醚与二硬脂酰基磷脂酰乙醇胺(脑磷脂)在羰基二咪唑的作用下缩合制备(转化率26%)(NoriyukiMaeda,YoshitoTakeuchi,MikiTakada,etal.Synthesisofangiogenesis-targetedpeptideandhydrophobizedpolyethyleneglycolconjugate.Bioorganic&MedicinalChemistryLetters,2004,14:1015-1017),另一类为将聚乙二醇或聚乙二醇单甲醚的羟基转化为羧基再转为有较高活性的中间体活性酯,然后与二硬脂酰基磷脂酰乙醇胺的氨基反应形成酰胺键(Shih-KwangWu,Ting-GungChang,Chin-Lu,etal.SolidPhaseMethodForSynthesisPeptide-Spacer-LipidConjugates,ConjugatesSynthesizedTherebyAndTargetedLiposomesContainingTheSame[P].US:0229017A1,2003-12-11)。这些制备方法都是使用高纯度的二硬脂酰基磷脂酰乙醇胺(脑磷脂)为原料,二硬脂酰基磷脂酰乙醇胺(脑磷脂)的分子量较大且结构比较复杂,其通常采用柱层析和全合成方法制备,反应步鄹较多,反应困难,产率较低,因此较纯净的二硬脂酰基磷脂酰乙醇胺(脑磷脂)的价格非常昂贵(阿拉丁的最新报价为3000元/25mg)。At present, the price of anti-cancer targeted drugs is generally high, which has an important relationship with the source of raw materials and preparation methods of the drug itself. Therefore, it is more important to choose low-cost raw materials and simple preparation methods. The currently reported methods for preparing MPEG-DSPE are roughly divided into two categories, one is the direct use of polyethylene glycol or polyethylene glycol monomethyl ether and distearyl phosphatidylethanolamine (cephalin) in carbonyl diimidazole Condensation preparation under action (conversion rate 26%) (NoriyukiMaeda, YoshitoTakeuchi, MikiTakada, etal.Synthesisofangiogenesis-targetedpeptideandhydrophobizedpolyethyleneglycolconjugate.Bioorganic&MedicinalChemistryLetters,2004,14:1015-1017), another kind is polyethylene glycol or polyethylene glycol The hydroxyl group of ether is converted into carboxyl and then converted into the intermediate active ester with higher activity, then reacts with the amino group of distearoyl phosphatidylethanolamine to form an amide bond (Shih-KwangWu, Ting-GungChang, Chin-Lu, et al.SolidPhaseMethodForSynthesisPeptide -Spacer-Lipid Conjugates, Conjugates Synthesized Thereby And Targeted Liposomes Containing The Same [P]. US: 0229017A1, 2003-12-11). These preparation methods all use high-purity distearoyl phosphatidylethanolamine (cephalin) as a raw material. Distearoyl phosphatidylethanolamine (cephalin) has a relatively large molecular weight and a relatively complex structure. It usually adopts column chromatography and It is prepared by total synthesis method, with many reaction steps, difficult reaction and low yield, so the price of relatively pure distearoylphosphatidylethanolamine (cephalin) is very expensive (the latest quotation of Aladdin is 3000 yuan/25mg) .
发明内容Contents of the invention
本发明的原理是:大豆磷脂主要由磷脂酰胆碱(卵磷脂)和磷脂酰乙醇胺(脑磷脂)组成,它是加工大豆油的一种副产物,价廉易得,其中的脑磷脂中的脂肪酸主要由油酸,亚油酸,棕榈酸,硬脂酸和亚麻酸组成,存在较多的不饱和脂肪酸,具有软化血管,降低胆固醇和降低血压的功能。用其作为原料制备的聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物(MPEG-SPE)不仅成本低于聚乙二醇单甲醚(二硬脂酰基磷脂酰乙醇胺(脑磷脂)衍生物(MPEG-DSPE)而且更有利于人类心血管的健康。The principle of the present invention is: soybean lecithin is mainly composed of phosphatidylcholine (lecithin) and phosphatidylethanolamine (cephalin), which is a by-product of processing soybean oil, which is cheap and easy to get, and the cephalin Fatty acids are mainly composed of oleic acid, linoleic acid, palmitic acid, stearic acid and linolenic acid, and there are more unsaturated fatty acids, which have the functions of softening blood vessels, lowering cholesterol and lowering blood pressure. The polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative (MPEG-SPE) prepared with it as a raw material is not only lower in cost than polyethylene glycol monomethyl ether (distearoylphosphatidylethanolamine (cephalin) derivative ( MPEG-DSPE) and more conducive to human cardiovascular health.
因此本发明针对现有的MPEG-DSPE制备所用脑磷脂原料难得,价格昂贵的特点。提供一种使用价格较便宜的天然大豆磷脂制备聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物药物辅料的方法。Therefore, the present invention aims at the rare and expensive characteristics of the cephalin raw materials used in the preparation of the existing MPEG-DSPE. The invention provides a method for preparing pharmaceutical auxiliary materials of polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivatives by using cheaper natural soybean lecithin.
本发明的另一个目的是提供一种聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物。Another object of the present invention is to provide a polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative.
实现本发明目的的技术解决方案是:一种聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物,其结构如下:The technical solution that realizes the object of the present invention is: a kind of polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative, its structure is as follows:
实现本发明另一目的的技术解决方案为:一种聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物的制备,具体步骤如下:The technical solution that realizes another object of the present invention is: a kind of preparation of polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative, concrete steps are as follows:
步骤1:以天然大豆磷脂制备大豆粉末磷脂;Step 1: preparing soybean powder phospholipids with natural soybean phospholipids;
步骤2:以聚乙二醇单甲醚制备聚乙二醇单甲醚羧基衍生物;Step 2: preparing polyethylene glycol monomethyl ether carboxyl derivatives with polyethylene glycol monomethyl ether;
步骤3:以聚乙二醇单甲醚羧基衍生物制备聚乙二醇单甲醚酰氯;Step 3: preparing polyethylene glycol monomethyl ether acid chloride with polyethylene glycol monomethyl ether carboxyl derivatives;
步骤4:以大豆粉末磷脂和聚乙二醇单甲醚酰氯为原料,以三氯甲烷为溶剂,以三乙胺为催化剂,制备聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物,反应条件为m(大豆粉末磷脂):m(聚乙二醇单甲醚酰氯)=1:1~10:1;反应温度为10℃~80℃;反应时间为0.5h~10h;Step 4: Using soybean powder phospholipids and polyethylene glycol monomethyl ether acid chloride as raw materials, using chloroform as a solvent, and triethylamine as a catalyst to prepare polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivatives, reaction conditions It is m (soybean powder phospholipid): m (polyethylene glycol monomethyl ether chloride) = 1: 1 ~ 10: 1; the reaction temperature is 10 ° C ~ 80 ° C; the reaction time is 0.5 h ~ 10 h;
步骤5:反应结束后,除去三氯甲烷和未反应的三乙胺,加入四氢呋喃沉淀出三乙胺的盐酸盐,离心分离,上层液体除去四氢呋喃再加入无水乙醚沉淀出反应产物。Step 5: After the reaction, remove chloroform and unreacted triethylamine, add tetrahydrofuran to precipitate triethylamine hydrochloride, centrifuge, remove tetrahydrofuran from the upper liquid, and then add anhydrous ether to precipitate the reaction product.
步骤1中所述的大豆粉末磷脂采用丙酮萃取法制备。The soybean powder phospholipid described in step 1 is prepared by an acetone extraction method.
步骤2中所述的聚乙二醇单甲醚羧基衍生物采用琼斯试剂氧化聚乙二醇单甲醚法制备,其中聚乙二醇单甲醚的分子量范围为1200~5000。The carboxyl derivative of polyethylene glycol monomethyl ether described in step 2 is prepared by using Jones reagent to oxidize polyethylene glycol monomethyl ether, wherein the molecular weight of polyethylene glycol monomethyl ether ranges from 1200 to 5000.
步骤3中所述的聚乙二醇单甲醚酰氯采用二氯亚砜和聚乙二醇单甲醚羧基衍生物制备。The polyethylene glycol monomethyl ether acid chloride described in step 3 is prepared by using thionyl chloride and polyethylene glycol monomethyl ether carboxyl derivatives.
步骤4中所述的聚乙二醇单甲醚酰氯与三乙胺的物质的量比为:n(聚乙二醇单甲醚酰氯):n(三乙胺)=1:10~1:40。The molar ratio of polyethylene glycol monomethyl ether chloride and triethylamine described in step 4 is: n (polyethylene glycol monomethyl ether chloride):n (triethylamine)=1:10~1: 40.
步骤5中所述的聚乙二醇单甲醚酰氯的物质的量与四氢呋喃体积之比为:n(聚乙二醇单甲醚酰氯(mmol)):v(四氢呋喃(ml))=1:30~1:100,所述的聚乙二醇单甲醚酰氯的物质的量与无水乙醚体积之比为n(聚乙二醇单甲醚酰氯(mmol)):v(无水乙醚(ml))=1:30~1:100。The ratio of the amount of polyethylene glycol monomethyl ether acid chloride to the volume of tetrahydrofuran described in step 5 is: n (polyethylene glycol monomethyl ether acid chloride (mmol)): v (tetrahydrofuran (ml))=1: 30 to 1:100, the ratio of the amount of polyethylene glycol monomethyl ether chloride to the volume of anhydrous ether is n (polyethylene glycol monomethyl ether chloride (mmol)): v (anhydrous ether ( ml))=1:30~1:100.
与现有的MPEG-DSPE药物辅料相比较,本发明结合了天然大豆磷脂的优点,一方面利用其含有的脑磷脂中存在较多的不饱和脂肪酸,具有软化血管,降低胆固醇和降低血压的功能,使其更有利于人体健康,另一方面利用其原料易得,价格便宜,降低了其生产成本,具有较大的经济效益和社会效益。通过以上方法制备的MPEG-SPE的技术效果为:通过TEM观察了MPEG-SPE在水中形成胶束的大小,结果表明,其在水溶液中形成的胶束平均粒径为100nm左右。通过荧光探针技术研究了MPEG-SPE的临界聚集浓度用以表征产物的热力学稳定性,结果表明其在水溶液中的临界胶束浓度为10-6mol/L左右,形成胶束的热力学稳定性优于小分子胶束。通过乳化力来表征MPEG-SPE的动力学稳定性,结果表明其的动力学稳定性优于大豆粉末磷脂,适合于制备靶向药物载体。Compared with the existing MPEG-DSPE pharmaceutical excipients, the present invention combines the advantages of natural soybean phospholipids, on the one hand, it utilizes the cephalin contained in it to contain more unsaturated fatty acids, which has the functions of softening blood vessels, lowering cholesterol and lowering blood pressure , making it more beneficial to human health, on the other hand, the raw materials are easy to get and the price is cheap, which reduces the production cost and has great economic and social benefits. The technical effect of the MPEG-SPE prepared by the above method is: the size of the micelles formed by the MPEG-SPE in water was observed by TEM, and the results showed that the average particle size of the micelles formed in the aqueous solution was about 100nm. The critical aggregation concentration of MPEG-SPE was studied by fluorescent probe technology to characterize the thermodynamic stability of the product. The results showed that its critical micelle concentration in aqueous solution was about 10 -6 mol/L, and the thermodynamic stability of the formed micelles Superior to small molecule micelles. The kinetic stability of MPEG-SPE was characterized by emulsification force, and the results showed that its kinetic stability was better than that of soybean powder phospholipids, and it was suitable for the preparation of targeted drug carriers.
附图说明Description of drawings
图1为本发明MPEG-SPE制备工艺流程图。Fig. 1 is the flow chart of the preparation process of MPEG-SPE of the present invention.
图2为本发明实施例1的MPEG2000-SPE浓度对I384/I373比值的影响图。Fig. 2 is a graph showing the influence of MPEG2000-SPE concentration on the I384/I373 ratio in Example 1 of the present invention.
具体实施方式detailed description
实施例1Example 1
图1中,第一步,称取12g大豆磷脂加入到100ml丙酮中,搅拌至固体出现,减压抽滤,滤饼加入到2支20ml离心管中,分别加入10ml丙酮,在4000r/min的转速下离心2min,倒出液体,重复多次上述过程,直至离心管中液体无色时,取出离心管中固体,放入真空干燥箱中室温干燥24h。In Figure 1, in the first step, weigh 12g of soybean lecithin and add it to 100ml of acetone, stir until solids appear, filter under reduced pressure, add the filter cake to two 20ml centrifuge tubes, add 10ml of acetone respectively, Centrifuge at a rotational speed for 2 minutes, pour out the liquid, and repeat the above process several times until the liquid in the centrifuge tube is colorless, take out the solid in the centrifuge tube, and put it in a vacuum drying oven to dry at room temperature for 24 hours.
第二步,称取5gmPEG2000加入盛有100mL丙酮溶液的500mL烧瓶中,在25℃下磁力搅拌直到mPEG全部溶解。然后加入4.25mL琼斯试剂,反应24h。反应结束后,加入异丙醇淬灭,抽滤,滤液加入50mL蒸馏水,旋蒸除去体系中的丙酮(尽量除尽),剩余溶液中加入一定量的碳酸氢钾,直至体系中无气泡产生为止,蒸干体系中的水,用三氯甲烷对残留物进行充分的萃取,抽滤,滤液旋蒸除去三氯甲烷,而后再向残余物中加入10%的盐酸溶液直至体系pH为1,蒸出水和氯化氢气体,残余物中有氯化钠析出,此时再用三氯甲烷萃取,抽滤,滤液旋蒸除去氯仿,得到产物,冷却后得到白色固体产物。产率:4.90g(98%)。酸值:实际值,0.497mmol羧基/g;理论值,0.500mmol羧基/g。IR:1735cm-1(羰基特征峰),3480cm-1(-OH的伸缩振动峰),1100cm-1(C—O—C的伸缩振动峰)。1HNMR(DMSOd6):δH3.24(-O-CH3),4.01(—O—CH2—COOH的次甲基),3.31-3.58(重复单元—CH2—CH2—O—),12.55(—COOH)。In the second step, weigh 5g of mPEG2000 into a 500mL flask filled with 100mL of acetone solution, and stir magnetically at 25°C until mPEG is completely dissolved. Then add 4.25mL Jones reagent and react for 24h. After the reaction is over, add isopropanol to quench, filter with suction, add 50mL distilled water to the filtrate, remove acetone in the system by rotary evaporation (remove as much as possible), and add a certain amount of potassium bicarbonate to the remaining solution until no bubbles are generated in the system , evaporate the water in the system to dryness, fully extract the residue with chloroform, filter with suction, remove the chloroform by rotary evaporation of the filtrate, then add 10% hydrochloric acid solution to the residue until the pH of the system is 1, evaporate Water and hydrogen chloride gas were discharged, and sodium chloride was precipitated in the residue. At this time, it was extracted with chloroform, filtered with suction, and the filtrate was rotary evaporated to remove chloroform to obtain the product. After cooling, a white solid product was obtained. Yield: 4.90 g (98%). Acid value: actual value, 0.497mmol carboxyl group/g; theoretical value, 0.500mmol carboxyl group/g. IR: 1735cm -1 (characteristic peak of carbonyl), 3480cm -1 (stretching vibration peak of -OH), 1100cm -1 (stretching vibration peak of C—O—C). 1 HNMR (DMSOd 6 ): δ H 3.24 (-O-CH 3 ), 4.01 (methine of -O-CH 2 -COOH), 3.31-3.58 (repeating unit -CH 2 -CH 2 -O-), 12.55 (—COOH).
第三步,称取2gCmPEG2000加入到10ml二氯甲烷中,再向反应体系中加入20ml二氯亚砜,回流反应6h。减压蒸馏,加入无水乙醚沉淀,抽滤,得到白色固体。In the third step, weigh 2g of CmPEG2000 and add it into 10ml of dichloromethane, then add 20ml of thionyl chloride into the reaction system, and react under reflux for 6h. Distill under reduced pressure, add anhydrous diethyl ether to precipitate, and filter with suction to obtain a white solid.
第四步,称取6.0g大豆粉末磷脂溶解到30ml三氯甲烷中,移入到150ml的三口烧瓶中,加入25mmol的三乙胺,磁力搅拌,升温到45,℃将2g聚乙二醇单甲醚2000酰氯溶解到20ml三氯甲烷中,使用滴液漏斗逐滴加入到三口烧瓶中。反应4h。The fourth step is to weigh 6.0g of soybean powder lecithin and dissolve it in 30ml of chloroform, transfer it into a 150ml three-neck flask, add 25mmol of triethylamine, stir it magnetically, heat up to 45, and dissolve 2g of polyethylene glycol monomethyl Ether 2000 acid chloride was dissolved in 20ml of chloroform, and added dropwise into a three-necked flask using a dropping funnel. Reaction 4h.
第五步,反应结束后,旋蒸除去三氯甲烷和未反应的三乙胺。而后加入30ml四氢呋喃沉淀出三乙胺的盐酸盐,离心分离,上层液体除去四氢呋喃再加入20ml无水乙醚沉淀出未反应的聚乙二醇单甲醚2000酰氯和反应产物,分别用10ml无水乙醚洗涤三次,干燥称重。IR:1650cm-1(—C(O)NH—的羰基伸缩振动峰),1533cm-1(—C(O)NH—的氨基面内弯曲振动峰),1100cm-1(C—O—C伸缩振动峰).In the fifth step, after the reaction is finished, chloroform and unreacted triethylamine are removed by rotary evaporation. Then add 30ml of tetrahydrofuran to precipitate the hydrochloride of triethylamine, centrifuge, remove tetrahydrofuran from the upper liquid, add 20ml of anhydrous ether to precipitate unreacted polyethylene glycol monomethyl ether 2000 acid chloride and reaction product, respectively use 10ml of anhydrous Washed three times with ether, dried and weighed. IR: 1650cm-1 (carbonyl stretching vibration peak of —C(O) NH—), 1533cm-1 (bending vibration peak of amino group in-plane of —C(O) NH—), 1100cm-1 (C—O—C stretching vibration peak vibration peak).
实施例2Example 2
第一步,同上first step, ditto
第二步,称取6gmPEG1200加入盛有100mL丙酮溶液的500mL烧瓶中,在25℃下磁力搅拌直到mPEG全部溶解。然后加入8.5mL琼斯试剂,反应24h。后处理方法同上。产率:5.61g(93.5%)。酸值:实际值,0.830mmol羧基/g;理论值,0.833mmol羧基/g。IR:1744cm-1(羰基特征峰),3486cm-1(-OH的伸缩振动峰),1088cm-1(C—O—C的伸缩振动峰)。1HNMR(DMSOd6):δH3.23(-O-CH3),4.01(—O—CH2—COOH的次甲基),3.33-3.50(重复单元—CH2—CH2—O—),12.54(—COOH)。In the second step, weigh 6g of mPEG1200 and add it into a 500mL flask containing 100mL of acetone solution, and stir magnetically at 25°C until mPEG is completely dissolved. Then add 8.5mL Jones reagent and react for 24h. The post-processing method is the same as above. Yield: 5.61 g (93.5%). Acid value: actual value, 0.830 mmol carboxyl group/g; theoretical value, 0.833 mmol carboxyl group/g. IR: 1744cm -1 (carbonyl characteristic peak), 3486cm -1 (stretching vibration peak of -OH), 1088cm -1 (stretching vibration peak of C—O—C). 1 HNMR (DMSOd 6 ): δ H 3.23 (-O-CH 3 ), 4.01 (methine of -O-CH 2 -COOH), 3.33-3.50 (repeating unit -CH 2 -CH 2 -O-), 12.54 (—COOH).
第三步,称取2gCmPEG1200加入到10ml二氯甲烷中,再向反应体系中加入30ml二氯亚砜,回流反应6h。减压蒸馏得到产物。In the third step, weigh 2g of CmPEG1200 and add it into 10ml of dichloromethane, then add 30ml of thionyl chloride into the reaction system, and react under reflux for 6h. The product was obtained by distillation under reduced pressure.
第四步,称取12.0g大豆粉末磷脂溶解到30ml三氯甲烷中,移入到150ml的三口烧瓶中,加入10mmol的三乙胺,磁力搅拌,升温到10,℃将1.2g聚乙二醇单甲醚1200酰氯溶解到20ml三氯甲烷中,使用滴液漏斗逐滴加入到三口烧瓶中。反应0.5h。The fourth step is to weigh 12.0g of soybean powder lecithin and dissolve it in 30ml of chloroform, transfer it into a 150ml three-neck flask, add 10mmol of triethylamine, stir it magnetically, heat up to 10°C and dissolve 1.2g of polyethylene glycol Dimethyl ether 1200 acid chloride was dissolved in 20ml of chloroform, and added dropwise into a three-neck flask using a dropping funnel. Reaction 0.5h.
第五步,反应结束后,旋蒸除去三氯甲烷和未反应的三乙胺。而后加入30ml四氢呋喃沉淀出三乙胺的盐酸盐,离心分离,上层液体除去四氢呋喃,冷却至10℃以下,再加入15ml无水乙醚沉淀出未反应的聚乙二醇单甲醚1200酰氯和反应产物,分别用5ml无水乙醚洗涤三次,干燥称重。IR:1653cm-1(—C(O)NH—的羰基伸缩振动峰),1537cm-1(—C(O)NH—的氨基面内弯曲振动峰),1090cm-1(C—O—C伸缩振动峰).In the fifth step, after the reaction is finished, chloroform and unreacted triethylamine are removed by rotary evaporation. Then add 30ml of tetrahydrofuran to precipitate triethylamine hydrochloride, centrifuge, remove tetrahydrofuran from the upper liquid, cool to below 10°C, add 15ml of anhydrous ether to precipitate unreacted polyethylene glycol monomethyl ether 1200 acid chloride and react The products were washed three times with 5 ml of anhydrous ether, dried and weighed. IR: 1653cm-1 (carbonyl stretching vibration peak of -C(O)NH-), 1537cm-1 (in-plane bending vibration peak of amino group of -C(O)NH-), 1090cm-1 (C—O—C stretching vibration peak vibration peak).
实施例3Example 3
第一步,同上first step, ditto
第二步,称取5gmPEG5000加入盛有100mL丙酮溶液的500mL烧瓶中,在25℃下磁力搅拌直到mPEG全部溶解。然后加入1.7mL琼斯试剂,反应24h。后处理方法同上。产率:4.91g(98.2%)。酸值:实际值,0.196mmol羧基/g;理论值,0.200mmol羧基/g。IR:1732cm-1(羰基特征峰),3480cm-1(-OH的伸缩振动峰),1106cm-1(C—O—C的伸缩振动峰)。1HNMR(DMSOd6):δH3.22(-O-CH3),4.01(—O—CH2—COOH的次甲基),3.33-3.51(重复单元—CH2—CH2—O—)n,12.54(—COOH)。In the second step, weigh 5g of mPEG5000 and add it into a 500mL flask filled with 100mL of acetone solution, and stir magnetically at 25°C until mPEG is completely dissolved. Then add 1.7mL Jones reagent and react for 24h. The post-processing method is the same as above. Yield: 4.91 g (98.2%). Acid value: actual value, 0.196 mmol carboxyl group/g; theoretical value, 0.200 mmol carboxyl group/g. IR: 1732cm -1 (carbonyl characteristic peak), 3480cm -1 (stretching vibration peak of -OH), 1106cm -1 (stretching vibration peak of C—O—C). 1 HNMR (DMSOd 6 ): δ H 3.22 (-O-CH 3 ), 4.01 (methine of —O—CH 2 —COOH), 3.33-3.51 (repeating unit—CH 2 —CH 2 —O—)n , 12.54 (—COOH).
第三步,称取5gCmPEG5000加入到10ml二氯甲烷中,再向反应体系中加入30ml二氯亚砜,回流反应6h。减压蒸馏,加入无水乙醚沉淀,抽滤,得到白色固体。In the third step, 5g of CmPEG5000 was weighed and added to 10ml of dichloromethane, and then 30ml of thionyl chloride was added to the reaction system, and the reaction was refluxed for 6h. Distill under reduced pressure, add anhydrous diethyl ether to precipitate, and filter with suction to obtain a white solid.
第四步,称取5g大豆粉末磷脂溶解到30ml三氯甲烷中,移入到150ml的三口烧瓶中,加入40mmol的三乙胺,磁力搅拌,升温到80,℃将5g聚乙二醇单甲醚5000酰氯溶解到20ml三氯甲烷中,使用滴液漏斗逐滴加入到三口烧瓶中。反应10h。Step 4: Dissolve 5g of soybean powder phospholipids into 30ml of chloroform, transfer to a 150ml three-necked flask, add 40mmol of triethylamine, stir magnetically, heat up to 80, ℃ and dissolve 5g of polyethylene glycol monomethyl ether 5000 g of acid chloride was dissolved in 20 ml of chloroform, and added dropwise into a three-necked flask using a dropping funnel. Reaction 10h.
第五步,反应结束后,旋蒸除去三氯甲烷和未反应的三乙胺。而后加入100ml四氢呋喃沉淀出三乙胺的盐酸盐,离心分离,上层液体旋蒸除去四氢呋喃再加入70ml无水乙醚沉淀出未反应的聚乙二醇单甲醚5000酰氯和反应产物,分别用10ml无水乙醚洗涤三次。干燥称重。IR:1655cm-1(—C(O)NH—的羰基伸缩振动峰),1533cm-1(—C(O)NH—的氨基面内弯曲振动峰),1106cm-1(C—O—C伸缩振动峰).In the fifth step, after the reaction is finished, chloroform and unreacted triethylamine are removed by rotary evaporation. Then add 100ml of tetrahydrofuran to precipitate the hydrochloride of triethylamine, centrifuge, remove the tetrahydrofuran by rotary evaporation of the upper layer liquid, then add 70ml of anhydrous ether to precipitate unreacted polyethylene glycol monomethyl ether 5000 acid chloride and the reaction product, respectively use 10ml Washed three times with anhydrous ether. Weigh dry. IR: 1655cm-1 (carbonyl stretching vibration peak of -C(O)NH-), 1533cm-1 (in-plane bending vibration peak of amino group of -C(O)NH-), 1106cm-1 (C—O—C stretching vibration peak vibration peak).
对实施例1制备的聚乙二醇单甲醚大豆磷脂酰乙醇胺衍生物进行了性能表征,其结果如下:The performance characterization of the polyethylene glycol monomethyl ether soybean phosphatidylethanolamine derivative prepared in Example 1 is carried out, and the results are as follows:
1.MPEG2000-SPE的胶束粒径:1. The micellar particle size of MPEG2000-SPE:
MPEG2000-SPE是一种聚合物表面活性剂,当其在水中浓度大于临界胶束浓度时可形成以疏水链端为核,亲水链端为核的纳米胶束,可以用来运输药物,当其达到一定的纳米尺寸时具有靶向特性。本部分采用透射电子显微镜测定MPEG2000-SPE的胶束粒径,方法如下:称取一定量的MPEG2000-SPE溶解于水中,常温放置3h,使得MPEG2000-SPE在水中形成稳定的胶束,沾到铜网上,铜网在室温下干燥后,在透射电镜上观察胶束的大小。实验结果表明,MPEG2000-SPE的胶束呈球形,平均粒径在100nm左右,粒子较均匀。MPEG2000-SPE is a polymer surfactant. When its concentration in water is greater than the critical micelle concentration, it can form nano-micelles with hydrophobic chain ends as the core and hydrophilic chain ends as the core. It can be used to transport drugs. It has targeting properties when it reaches a certain nanometer size. In this part, transmission electron microscopy is used to measure the micelle particle size of MPEG2000-SPE. The method is as follows: Weigh a certain amount of MPEG2000-SPE and dissolve it in water, and place it at room temperature for 3 hours, so that MPEG2000-SPE forms stable micelles in water and sticks to copper. On the grid, the size of the micelles was observed on a TEM after the copper grid was dried at room temperature. The experimental results show that the micelles of MPEG2000-SPE are spherical, the average particle diameter is about 100nm, and the particles are relatively uniform.
2.MPEG2000-SPE的热力学稳定性研究:2. Thermodynamic stability research of MPEG2000-SPE:
MPEG2000-SPE在水溶液中可形成胶束,胶束热力学的稳定性指的是聚合物胶束向单体解聚时的浓度,即临界胶束浓度(CMC)也成临界聚集浓度(CAC)。本部分采用灵敏度较高的荧光探针技术来测定MPEG2000-SPE的CAC。方法如下:首先制备1×10-7,2×10-7,3×10-7,5×10-7,7×10-7,1×10-6,2×10-6,3×10-6,5×10-6,1×10-5,2×10-5,3×10-5,5×10-5,7×10-5,10×10-5,15×10-5mol/L浓度的MPEG-SPE溶液,再配置2×10-4mol/L的芘的丙酮溶液,而后取0.1ml芘的丙酮溶液加入10ml容量瓶中,常温下使丙酮挥发掉,用移液枪分别移取10ml上述配置的MPEG2000-SPE溶液加入到容量瓶中,多次震荡后再超声30min。然后在335nm下测定一系列不同浓度的MPEG-SPE溶液在373nm和384nm下的荧光强度,以MPEG2000-SPE浓度的对数为X轴,I384/I373的值为Y轴作图,从图中找出达到CAC时的浓度,如图2所示,当x=-5.69时,I384/I373的值发生突变,说明此时已到达CAC,临界胶束浓度为2×10-6mol/L,远远小于小分子的临界胶束浓度10-3mol/L,因此MPEG-SPE的热力学稳定性优于小分子胶束。MPEG2000-SPE can form micelles in aqueous solution. The thermodynamic stability of micelles refers to the concentration of polymer micelles when they depolymerize to monomers, that is, the critical micelle concentration (CMC) is also the critical aggregation concentration (CAC). In this part, the fluorescent probe technology with high sensitivity is used to measure the CAC of MPEG2000-SPE. The method is as follows: first prepare 1×10 -7 , 2×10 -7 , 3×10 -7 , 5×10 -7 , 7×10 -7 , 1×10 -6 , 2×10 -6 , 3×10 -6 , 5×10 -6 , 1×10 -5 , 2×10 -5 , 3×10 -5 , 5×10 -5 , 7×10 -5 , 10×10 -5 , 15×10 -5 mol/L concentration of MPEG-SPE solution, and then configure 2×10 -4 mol/L pyrene in acetone solution, then take 0.1ml of pyrene in acetone solution and add it to a 10ml volumetric flask. Pipette 10ml of the above-mentioned MPEG2000-SPE solution into the volumetric flask, and then sonicate for 30min after shaking several times. Then measure the fluorescence intensity of a series of MPEG-SPE solutions with different concentrations at 373nm and 384nm at 335nm, take the logarithm of the MPEG2000-SPE concentration as the X-axis, and the value of I384/I373 as the Y-axis plot, find out from the figure As shown in Figure 2, when x=-5.69, the value of I384/I373 changes abruptly, indicating that the CAC has been reached at this time, and the critical micelle concentration is 2×10 -6 mol/L, far from Much smaller than the critical micelle concentration of small molecules (10 -3 mol/L), the thermodynamic stability of MPEG-SPE is better than that of small molecule micelles.
3.MPEG2000-SPE的胶束动力学稳定性研究:3. MPEG2000-SPE study on the kinetic stability of micelles:
聚合物胶束的稳定性通常由热力学稳定性和动力学稳定性评价,其中动力学稳定性是指胶束分解为单体的速度,我们设计由正己烷和水形成的乳状液体系,根据乳状液分离一定体积的液体来表征胶束分解为单体的速度,同等条件下与大豆粉末磷脂进行对比。操作如下:用50ml的蒸馏水溶解0.05g试样,置于100ml的具塞量筒内,量取50ml的正己烷,塞上盖子猛烈振动至充分乳化后,立即计时测定水-油相分开10ml所耗费的时间。实验结果如表1所示:MPEG2000-SPE分开10ml所用时间为183s远远大于大豆粉末磷脂所用时间6s,并且当MPEG-SPE的乳液分出41ml体积后油-水将不再分离,量筒上部呈现稳定的凝胶状态。因此MPEG-SPE的动力学稳定性优于大豆粉末磷脂。The stability of polymer micelles is usually evaluated by thermodynamic stability and kinetic stability. Kinetic stability refers to the speed at which micelles decompose into monomers. We design an emulsion system formed by n-hexane and water. According to the emulsion Liquid separation of a certain volume of liquid to characterize the speed at which micelles decompose into monomers, compared with soybean powder phospholipids under the same conditions. The operation is as follows: dissolve 0.05g sample with 50ml of distilled water, place it in a 100ml stoppered measuring cylinder, measure 50ml of n-hexane, put on the lid and vibrate violently until it is fully emulsified, then measure the water-oil phase separation of 10ml by time immediately time. The experimental results are shown in Table 1: the time taken by MPEG2000-SPE to separate 10ml is 183s, which is far longer than the time taken by soybean powder phospholipids of 6s, and when the MPEG-SPE emulsion is separated into a volume of 41ml, the oil-water will no longer separate, and the upper part of the measuring cylinder will appear stable gel state. Therefore, the kinetic stability of MPEG-SPE is better than soybean powder phospholipids.
表1不同物质的油水两相分开体积与所用时间(s)之间的关系Table 1 The relationship between the volume of oil-water two-phase separation of different substances and the time (s) used
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310541744.XA CN103626993B (en) | 2013-11-05 | 2013-11-05 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310541744.XA CN103626993B (en) | 2013-11-05 | 2013-11-05 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103626993A CN103626993A (en) | 2014-03-12 |
CN103626993B true CN103626993B (en) | 2016-01-20 |
Family
ID=50208461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310541744.XA Expired - Fee Related CN103626993B (en) | 2013-11-05 | 2013-11-05 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103626993B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3886579T3 (en) * | 2018-11-30 | 2023-08-28 | Icoat Medical Ab | EX VIVO ORGAN TREATMENT USING PEG-PHOSPHOLIPIDE MOLECULES |
CN112390942A (en) * | 2019-08-17 | 2021-02-23 | 南京理工大学 | Hydroxylated soybean phosphatidylethanolamine-methoxypolyethylene glycol, preparation method and application thereof |
CN114796055B (en) * | 2022-05-19 | 2023-08-15 | 广东艾粒生物科技有限责任公司 | Whitening dressing rich in liposome nanoparticles and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100486646C (en) * | 2007-01-17 | 2009-05-13 | 东南大学 | Polyethylene glycol-phosphatidyl ethanolamine polymer or medicinal acid addition salt and application thereof in pharmacy |
CN102649841A (en) * | 2012-04-06 | 2012-08-29 | 东南大学 | Polyethylene glycol-modified phospholipid derivative taking anilino-quinazoline as targeting ligand and preparation method thereof |
CN103263674A (en) * | 2013-05-08 | 2013-08-28 | 上海纳米技术及应用国家工程研究中心有限公司 | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
-
2013
- 2013-11-05 CN CN201310541744.XA patent/CN103626993B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100486646C (en) * | 2007-01-17 | 2009-05-13 | 东南大学 | Polyethylene glycol-phosphatidyl ethanolamine polymer or medicinal acid addition salt and application thereof in pharmacy |
CN102649841A (en) * | 2012-04-06 | 2012-08-29 | 东南大学 | Polyethylene glycol-modified phospholipid derivative taking anilino-quinazoline as targeting ligand and preparation method thereof |
CN103263674A (en) * | 2013-05-08 | 2013-08-28 | 上海纳米技术及应用国家工程研究中心有限公司 | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
Non-Patent Citations (1)
Title |
---|
聚乙二醇单甲醚羧基衍生物的制备;陈龙等;《精细化工》;20131031;第30卷(第10期);第1177-1180、1197页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103626993A (en) | 2014-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Drug delivery using nanoparticle-stabilized nanocapsules | |
Lesoin et al. | Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method | |
CN105056213B (en) | A kind of supermolecule nano ball of glucose responding and its preparation method and application | |
CN103626993B (en) | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof | |
Qindeel et al. | New, environment friendly approach for synthesis of amphiphilic PCL–PEG–PCL triblock copolymer: an efficient carrier for fabrication of nanomicelles | |
Liu et al. | Preparation and characterization of paclitaxel/chitosan nanosuspensions for drug delivery system and cytotoxicity evaluation in vitro | |
CN103284950B (en) | Sebum liposome and preparation method for same | |
Kashyap et al. | Thermo-responsive and shape transformable amphiphilic scaffolds for loading and delivering anticancer drugs | |
Arshad et al. | Synthesis of lipid-based amphiphilic block copolymer and its evaluation as nano drug carrier | |
CN102391498A (en) | Polyethylene glycol di-fatty acid glyceride derivatives and application thereof to medicine delivery | |
CN101343540A (en) | Method for preparing quantum dots using hyperbranched polymer supramolecular nanoreactor | |
CN105326792B (en) | Target liposomes wrap up the preparation method of aqueous phase nano-Au composite | |
JP2019518096A (en) | Amphiphilic polymer | |
Demirdogen et al. | Preparation of novel CaMoO4: Eu3+-MCM-41 nanocomposites and their applications and monitoring as drug release systems | |
Wang et al. | Micellization and single-particle encapsulation with dimethylammoniopropyl sulfobetaines | |
CN106083993B (en) | Amphiphilic polypeptide dendrimers and preparation methods thereof | |
Guo et al. | Well-defined podophyllotoxin polyprodrug brushes: preparation via RAFT polymerization and evaluation as drug carriers | |
Wu et al. | Synthesis and micellization of a new amphiphilic star-shaped poly (D, L-lactide)/polyphosphoester block copolymer | |
Wu et al. | Synthesis and micellization of amphiphilic biodegradable methoxypolyethylene glycol/poly (d, l-lactide)/polyphosphate block copolymer | |
CN104689321B (en) | Curcumin long-circulating nanoliposome carrier of enoxolone mediation and preparation method thereof | |
Li et al. | Self-assembly of nanoparticles from cyclotriphosphazenes grafted with hexa-[p-(carbonyl tryptophan ethyl ester) phenoxy)] group | |
CN107412181B (en) | Preparation method for controlling release of lipid nanoparticles by using amphiphilic bletilla striata gum skeleton | |
Guo et al. | A codendrimer of PAMAM decorated with oligoethylene glycol dendrons: synthesis, self-assembly, and application as a drug carrier | |
CN109172524A (en) | A kind of Puerarin micella and preparation method thereof, puerarin preparation | |
CN108186573A (en) | It is a kind of using lipid encapsulation mesoporous silicon oxide as hydroxycamptothecin Liver targeting preparation of carrier and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20211105 |